Sana Biotechnology (NASDAQ:SANA) Announces Quarterly Earnings Results

Sana Biotechnology (NASDAQ:SANA) released its earnings results on Monday. The company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.15) by $0.01, FiscalAI reports.

Sana Biotechnology Price Performance

Shares of SANA traded up $0.05 during midday trading on Monday, reaching $3.56. The stock had a trading volume of 2,270,317 shares, compared to its average volume of 2,775,120. The company has a market capitalization of $961.16 million, a P/E ratio of -3.67 and a beta of 2.17. The firm’s 50 day moving average price is $3.36 and its 200-day moving average price is $4.04. Sana Biotechnology has a 52 week low of $1.60 and a 52 week high of $6.55.

Institutional Trading of Sana Biotechnology

Large investors have recently added to or reduced their stakes in the company. Mercer Global Advisors Inc. ADV acquired a new stake in shares of Sana Biotechnology during the third quarter worth approximately $36,000. Russell Investments Group Ltd. purchased a new position in Sana Biotechnology in the third quarter valued at about $39,000. Jacobi Capital Management LLC acquired a new stake in Sana Biotechnology in the fourth quarter valued at approximately $41,000. BNP Paribas Financial Markets boosted its position in shares of Sana Biotechnology by 46.9% in the second quarter. BNP Paribas Financial Markets now owns 15,444 shares of the company’s stock valued at $42,000 after acquiring an additional 4,931 shares during the period. Finally, Captrust Financial Advisors grew its stake in shares of Sana Biotechnology by 43.8% in the second quarter. Captrust Financial Advisors now owns 15,793 shares of the company’s stock worth $43,000 after acquiring an additional 4,807 shares during the last quarter. 88.23% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on SANA. Weiss Ratings lowered shares of Sana Biotechnology from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, May 1st. Zacks Research lowered Sana Biotechnology from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, March 3rd. Wall Street Zen upgraded Sana Biotechnology from a “strong sell” rating to a “sell” rating in a report on Saturday. Morgan Stanley reiterated an “overweight” rating and set a $12.00 target price on shares of Sana Biotechnology in a research note on Friday, March 13th. Finally, Wedbush increased their price objective on shares of Sana Biotechnology from $6.00 to $7.00 and gave the company an “outperform” rating in a research note on Tuesday, April 14th. Seven research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Sana Biotechnology has an average rating of “Moderate Buy” and an average target price of $9.50.

About Sana Biotechnology

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.